Evidence map›Paper›PMID 26854123›Full record

Trial reportDiabetes, obesity & metabolism2016

Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial.

R Aronson, Y Reznik, I Conget, J A Castañeda, S Runzis, S W Lee, O Cohen, OpT2mise Study Group

Open access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Addressing the Burden of Multiple Daily Insulin Injections in Type 2 Diabetes with Insulin Pump Technology: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Review
  7. Article
  8. Article
  9. Insulin Delivery Hardware: Pumps and Pens.Diabetes technology & therapeutics · 2022
    Article
  10. Article
  11. Review
  12. Article
  13. Key Features of Insulin Delivery Devices for Type 2 Diabetes: Type 2.0 Booth Survey.Clinical diabetes : a publication of the American Diabetes Association · 2020
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 8 countries.

R AronsonLMC Diabetes and Endocrinology, Toronto, ON, Canada.
Y ReznikDepartment of Endocrinology, University of Caen Côte de Nacre Regional Hospital Center, Caen, France.
I CongetDiabetes Unit, Endocrinology and Nutrition Department, University Hospital Clinic, Barcelona, Spain.
J A CastañedaMedtronic Bakken Research Center, Maastricht, The Netherlands.
S RunzisMedtronic International Trading Sàrl, Tolochenaz, Switzerland.
S W LeeMedtronic Diabetes, Northridge, CA, USA.
O CohenInstitute of Endocrinology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
OpT2mise Study Group
Hospital Clínic de Barcelona · ESLMC Diabetes & Endocrinology (Canada) · CAMedtronic (Netherlands) · NLMedtronic (Switzerland) · CHMedtronic (United States) · USSheba Medical Center · ILUniversité de Caen Normandie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo compare insulin pump therapy and multiple daily injections (MDI) in patients with type 2 diabetes receiving basal and prandial insulin analogues.

methodsAfter a 2-month dose-optimization period, 331 patients with glycated haemoglobin (HbA1c) levels ≥8.0% and ≤12% were randomized to pump therapy or continued MDI for 6 months [randomization phase (RP)]. The MDI group was subsequently switched to pump therapy during a 6-month continuation phase (CP). The primary endpoint was the between-group difference in change in mean HbA1c from baseline to the end of the RP.

resultsThe mean HbA1c at baseline was 9% in both groups. At the end of the RP, the reduction in HbA1c was significantly greater with pump therapy than with MDI (-1.1 ± 1.2% vs -0.4 ± 1.1%; p < 0.001). The pump therapy group maintained this improvement to 12 months while the MDI group, which was switched to pump therapy, showed a 0.8% reduction: the final HbA1c level was identical in both arms. In the RP, total daily insulin dose (TDD) was 20.4% lower with pump therapy than with MDI and remained stable in the CP. The MDI-pump group showed a 19% decline in TDD, such that by 12 months TDD was equivalent in both groups. There were no differences in weight gain or ketoacidosis between groups. In the CP, one patient in each group experienced severe hypoglycaemia.

conclusionsPump therapy has a sustained durable effect on glycaemic control in uncontrolled type 2 diabetes.

Indexed as

Insulin Infusion SystemsAgedCohort StudiesDiabetes Mellitus, Type 2Drug Administration ScheduleDrug MonitoringDrug ResistanceFemaleGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInjections, SubcutaneousInsulinInsulin, Long-ActingGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinInsulin, Long-ActingInsulin, Short-Actingcontinuous subcutaneous insulin infusioninsulin pumpmultiple daily injectionstype 2 diabetes

Identifiers

PMID26854123
PMCPMC5071718
OpenAlexW2267584932

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.